Great early results in clinical trials
- Elegant, minimally invasive procedure
- Retraction of lateral lobes without the need to cut, burn or puncture tissue
- Fully reversible if needed
Interview with a Butterfly patient
BPH is the non-cancerous enlargement of the prostate, effecting affecting 50% of men above 60 and more than 70% of men above 70.
BPH symptoms have a significant effect on the quality of life.
Approximately 30 million men around the world experience some level of BPH symptoms and about 25% of those men will actively seek treatment.
company
Patrick brings more than 20 years of experience in the medtech industry.
Most recently, Patrick was the Business Unit VP, Urology and GYN at Olympus, leading the commercial launch of a BPH treatment in the US
Idan brings more than 18 year of commercial and business experience in the medical device industry.
Portfolio includes: FlowMedic (CEO), Abbott Vascular (marketing), MCS (marketing), Biotronik (sales)
Idan holds a BSc. in engineering and an MBA
One of Israel’s leading medical entrepreneurs.
Founded and invested in more than 20 startups.
Portfolio includes: Lumenis, Syneron, Rapid Medical, Tulip, RealView, Ventor
Adrian is a certified urologist with deep understanding of the BPH market.
A serial entrepreneur, Adrian brings years of experience in developing innovative medical technologies.
Portfolio includes: EON Surgical, Orthospace, Vibrant, Clip-Tip Medical, Saturix, Stepwise
Yehuda is a mechanical engineer and a serial entrepreneur, bringing many years of experience in developing medical technologies
Portfolio includes: Clip-Tip Medical, Saturix, EON Surgical, SteadyMed.
Yehuda holds a BSc. in mechanical engineering
Vardit brings more than 15 years of experience in clinical and regulatory leadership positions, leading clinical and regulatory efforts in the US and various other countries.
Vardit holds a PhD in Biomedical Engineering
Over the last 20 years, Mr. Hovard has held multiple leadership roles at subsidiaries of Coloplast, a publicly-traded global medical device company. Most recently, he served as the President of Interventional Urology from 2011 to 2019. At Interventional Urology, Mr. Hovard operated in a CEO capacity leading approximately 900 employees across corporate development with complete oversight of R&D, operations/manufacturing, marketing, sales, human resources, finance and legal
news
Butterfly Medical secures funding from the European Innovation Council (EIC).
The funding includes a non-dilutive grant of up to Euro 2.5M, as well as participation in future equity financing round.
The EIC process is highly competitive and the successful completion of the process is another vote of confidence in the company and its unique technology.
https://www.linkedin.com/feed/update/urn:li:activity:7077651723946704897/
Butterfly Medical Mr. Patrick MacCarthy as the new CEO to lead the company into the commercialization phase.
Until recently, Patrick served as the Business Unit VP- Urology and GYN at Olympus, among other things, Patrick launched in the US market a minimally invasive BPH treatment.
In addition, Patrick brings more than 20 years of experience in the medical device industry, in both small companies and large corporations.
https://www.prnewswire.com/news-releases/butterfly-medical-welcomes-experienced-urology-executive-to-its-helm-302136048.htmlevents
Butterfly Medical participated in the American Urology Association annual conference, held this year in San Antonio, TX.
The conference offered a great opportunity to meet with leading urologists and urology-focused companies and to learn of the recent developments in our space.
https://www.linkedin.com/feed/update/urn:li:activity:7193756732999770112
Butterfly Medical
Address
Beit Tavor 2nd entrance, 3rd floor, Yokneam 20692, Israel
office@butterfly-medical.com